StimLabs Launches First FDA-Cleared Human Umbilical Cord Particulate Device for Wound Management
核心洞察
StimLabs announces the commercial launch of Allacor P (搜索), the first FDA 510(k) cleared medical device derived from human umbilical cord extracellular matrix for wound management applications.
The device received FDA clearance in February 2024 and was awarded an A Code in 2025, enabling expanded access to additional sites of care beyond hospitals.
Allacor P (搜索) retains structural ECM components rich in hyaluronic acid and collagen I, with a unique particulate format designed to conform to irregular and complex wounds.
StimLabs, a regenerative medicine company based in Roswell, Georgia, has announced the commercial launch of Allacor P (搜索), marking a significant milestone as the first FDA 510(k) cleared medical device derived from human umbilical cord extracellular matrix (ECM) for wound management. The device received FDA clearance in February 2024 alongside the umbilical cord-derived hospital solution Corplex P (搜索).
Regulatory Milestones and Market Access
Allacor P (搜索) was awarded an A Code in 2025, a critical regulatory achievement that allows StimLabs to expand the device's availability to additional sites of care beyond hospital settings. This designation provides healthcare practitioners with broader access to the technology for managing both acute and chronic wounds.
Since receiving FDA clearance, StimLabs has focused on building scientific data and compiling real-world clinical feedback to support informed product use as the company expands into new care settings.
Device Characteristics and Clinical Applications
The device retains structural ECM components and is rich in hyaluronic acid and collagen I, key components for wound healing applications. Allacor P (搜索)'s unique particulate format enables versatile application processes and allows the device to conform to irregular, complex wounds that may be challenging to treat with traditional wound care approaches.
The device is indicated for managing a range of acute and chronic wounds, addressing a significant clinical need in wound care management.
Clinical Experience and Provider Feedback
Leading wound care clinician Dr. R. Daniel Davis has provided positive feedback on the device's clinical performance. According to Dr. Davis, the dehydrated human umbilical cord particulate device "has the potential to impact so many patients in the same way it did for a recent complex case of mine. The dramatic improvement after just one application brought hope to my patient during a challenging time. I'm an advocate for this device; it's something providers need to try."
Company Background and Strategic Focus
StimLabs positions itself as a pioneer in advancing regenerative medicine, with current focus areas in wound care and surgical applications. The company describes its mission as providing patients with optimal care while addressing urgent needs in areas with limited treatment options.
The company maintains a comprehensive product portfolio addressing various clinical applications and has established what it describes as a strong intellectual property catalog. StimLabs emphasizes its role as a trusted partner to both physicians and patients in the regenerative medicine space.